PE20142448A1 - Compuestos de n-alquiltriazol como antagonistas de lpar - Google Patents

Compuestos de n-alquiltriazol como antagonistas de lpar

Info

Publication number
PE20142448A1
PE20142448A1 PE2014002232A PE2014002232A PE20142448A1 PE 20142448 A1 PE20142448 A1 PE 20142448A1 PE 2014002232 A PE2014002232 A PE 2014002232A PE 2014002232 A PE2014002232 A PE 2014002232A PE 20142448 A1 PE20142448 A1 PE 20142448A1
Authority
PE
Peru
Prior art keywords
compounds
alkyltriazole
lpar
antagonists
triazol
Prior art date
Application number
PE2014002232A
Other languages
English (en)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Matthew C Lucas
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142448(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20142448A1 publication Critical patent/PE20142448A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A COMPUESTOS DE N-ALQUILTRIAZOL DE FORMULA (I) DONDE R1, R2, R3 Y R4 SON COMO SE DESCRIBE EN LA MEMORIA DESCRIPTIVA. SON COMPUESTOS PREFERIDOS: ACIDO 1-(4'-{1-METIL-5-[1-(3-TRIFLUOROMETIL-FENIL)-ETOXICARBONILAMINO]-1H-[1,2,3]TRIAZOL-4-IL}-BIFENIL-4-IL)-CICLOPROPANOCARBOXILICO; ACIDO {4'-[1-METIL-5-((R)-1-FENIL-ETOXICARBONILAMINO)-1H-[1,2,3]TRIAZOL-4-IL]-BIFENIL-4-IL}-ACETICO; ENTRE OTROS. TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DEL ACIDO LISOFOSFATIDICO (LPAR) SIENDO UTILES PARA EL TRATAMIENTO DE FIBROSIS PULMONAR
PE2014002232A 2012-06-20 2013-06-17 Compuestos de n-alquiltriazol como antagonistas de lpar PE20142448A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261661961P 2012-06-20 2012-06-20

Publications (1)

Publication Number Publication Date
PE20142448A1 true PE20142448A1 (es) 2015-01-28

Family

ID=48628667

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014002232A PE20142448A1 (es) 2012-06-20 2013-06-17 Compuestos de n-alquiltriazol como antagonistas de lpar

Country Status (22)

Country Link
US (1) US9321738B2 (es)
EP (1) EP2864300A1 (es)
JP (1) JP2015520202A (es)
KR (1) KR20150021057A (es)
CN (1) CN104411692A (es)
AU (1) AU2013279512A1 (es)
BR (1) BR112014030685A2 (es)
CA (1) CA2869541A1 (es)
CL (1) CL2014003243A1 (es)
CO (1) CO7131358A2 (es)
CR (1) CR20140525A (es)
EA (1) EA201492285A1 (es)
HK (1) HK1206342A1 (es)
IL (1) IL236088A0 (es)
IN (1) IN2014DN09348A (es)
MA (1) MA37764A1 (es)
MX (1) MX2014014710A (es)
PE (1) PE20142448A1 (es)
PH (1) PH12014502789A1 (es)
SG (1) SG11201407220YA (es)
UA (1) UA109868C2 (es)
WO (1) WO2013189864A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
MA37762B1 (fr) * 2012-06-20 2018-04-30 Hoffmann La Roche Composés n-aryltriazole utilisés comme antagonistes de lpar
CA2906931C (en) 2013-03-15 2023-03-14 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
CN106458964B (zh) 2014-06-27 2019-11-22 宇部兴产株式会社 卤素取代杂环化合物的盐
AR108838A1 (es) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
KR20200100724A (ko) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 n-연결된 카르바모일 시클로헥실 산
CN111699180A (zh) 2017-12-19 2020-09-22 百时美施贵宝公司 作为lpa拮抗剂的吡唑n-连接的氨基甲酰基环己基酸
TW202017918A (zh) * 2017-12-19 2020-05-16 美商必治妥美雅史谷比公司 作為lpa拮抗劑之環己基酸三唑吖
WO2019126087A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
KR20200100723A (ko) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 피라졸 아진
RS62710B1 (sr) * 2017-12-19 2022-01-31 Bristol Myers Squibb Co Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti
EP3728240B1 (en) * 2017-12-19 2022-06-29 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
EP3727589B1 (en) 2017-12-19 2022-06-29 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as lpa antagonists
ES2943661T3 (es) 2017-12-19 2023-06-15 Bristol Myers Squibb Co Acidos carbamoil ciclohexílicos pirazol-O-ligados como antagonistas de LPA
KR20200100713A (ko) * 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 트리아졸 아졸
WO2019126086A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as lpa antagonists
MX2020006414A (es) * 2017-12-29 2020-09-17 Biomarin Pharm Inc Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
CN113473985A (zh) * 2018-09-18 2021-10-01 百时美施贵宝公司 作为lpa拮抗剂的环戊酸
WO2020060916A1 (en) * 2018-09-18 2020-03-26 Bristol-Myers Squibb Company Cycloheptyl acids as lpa antagonists
KR20210060546A (ko) * 2018-09-18 2021-05-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 옥사비시클로 산
AU2020384883B2 (en) * 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
JP2023529369A (ja) 2020-06-03 2023-07-10 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
CA3183097A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
AU2022273631A1 (en) 2021-05-11 2023-11-02 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
PE20140879A1 (es) * 2010-12-07 2014-08-06 Amira Pharmaceuticals Inc Antagonistas del receptor de acido lisofosfatidico para el tratamiento de fibrosis
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
EP2744807A4 (en) * 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
HK1206342A1 (en) 2016-01-08
CR20140525A (es) 2015-01-12
EA201492285A1 (ru) 2015-04-30
EP2864300A1 (en) 2015-04-29
MX2014014710A (es) 2015-03-04
KR20150021057A (ko) 2015-02-27
WO2013189864A1 (en) 2013-12-27
BR112014030685A2 (pt) 2017-06-27
US20150133511A1 (en) 2015-05-14
UA109868C2 (ru) 2015-10-12
MA37764A1 (fr) 2016-01-29
IL236088A0 (en) 2015-02-01
IN2014DN09348A (es) 2015-07-17
US9321738B2 (en) 2016-04-26
CL2014003243A1 (es) 2015-03-20
PH12014502789A1 (en) 2015-02-09
CN104411692A (zh) 2015-03-11
AU2013279512A1 (en) 2014-10-16
CA2869541A1 (en) 2013-12-27
JP2015520202A (ja) 2015-07-16
SG11201407220YA (en) 2014-12-30
CO7131358A2 (es) 2014-12-01

Similar Documents

Publication Publication Date Title
PE20142448A1 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
PE20142305A1 (es) Compuestos de n-ariltriazol como antagonistas de lpar
PE20170502A1 (es) ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6
PE20190211A1 (es) Acidos de carbamoiloximetil triazol ciclohexilo como antagonistas de acido lisofosfatidico (lpa)
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
UY32327A (es) Antagonistas de receptores de ácido lisofosfatídico
CR20140057A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-etoxi-etil}-1h-[1,2,4]triazol sustituidos
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
MX2012008361A (es) Compuestos de pirazol como antagonistas de crth2.
CL2011003072A1 (es) Compuestos derivados de 4´-(isoxazol-5-il)-bifenil-4-il-cicloalquil(c3-8), antagonistas del receptor de acido lisofosfatidico; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, problemas pulmonares, entre otras.
EA201591662A1 (ru) Липиды и липидные композиции для доставки активных агентов
MX354102B (es) Derivados de bencimidazol-prolina.
CL2008003181A1 (es) Sal del acido 3-[5-(piridin-2-il-metoxi)-3-(2-metil-2-propiltio)-1-[4-(2-metoxipiridin-5-il)bencil]-indol-2-il]-2,2-dimetil-propionico; fromas crsitalinas de la sal sodica; proceso de preparacion; composiciones farmaceuticas; kit farmaceutico, y uso para el tratamiento de asma.
CU20160007A7 (es) Derivados de 2((( oxadiazol/triazol/tetrazol/isoxazol) metil) fenil)-1-(heterociclil)-ona como inhibidores activos de autotaxina
BR112012017442A2 (pt) derivados de triazol bicíclicos substituídos como moduladores de gamma secretase
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
EA201400553A1 (ru) Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
PE20141607A1 (es) Compuestos heterociclicos, medicamentos que los contienen, uso de aquellos y procesos para su preparacion
UA109867C2 (ru) Замещенные соединения пиразола как антагонисты рецепторов лизофосфатидной кислоты (lpar)
CL2018000057A1 (es) Composiciones farmacéuticas que comprenden un antagonista de la integrina alfa4 para uso en el tratamiento de afecciones inflamatorias oculares
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
PE20160846A1 (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c
MX364610B (es) Derivados de 1- [m-carboxamido (hetero) aril-metil]-heterociclil-c arboxamida.

Legal Events

Date Code Title Description
FD Application declared void or lapsed